Barry Bannister, Stifel chief equity strategist, joins 'The Exchange' to discuss the markets, his bearish take on risks in ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $100.25, a high estimate of ...

Stifel Financial Corp. is facing allegations that it’s paying unreasonable administrative fees for its employee retirement ...

Stifel warns of a 12% decline in the S&P 500 index in the back half of 2025. Its strategist Barry Bannister explained why in ...

Paul Kilfoy has joined Bank of America Merrill Lynch as director, senior sales trader. The move sees Toronto-based Kilfoy ...

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is among the best growth stocks to invest in for the next 5 years. Analysts at ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

The company's share price was up 4.6% as of 1:40 p.m. ET, amid a 0.2% gain for the S&P 500 (SNPINDEX: ^GSPC) and a 0.1% gain ...

Cruise operators have fought hard against the plan, arguing they drop off passengers who patronize Mexican businesses.

Oracle shares surged to an all-time high Monday as CEO Safra Catz touted a “strong start” to fiscal 2026 for the tech giant, with several new cloud deals.

Stifel upgrades Oracle to 'Buy' with a $250 target, citing sustainable cloud growth and efficient spending. Analyst Brad ...